- Home
- LFVN vs OBIO Comparison
LFVN vs OBIO Comparison
Compare LFVN & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFVN
- OBIO
- Stock Information
- Founded
- LFVN N/A
- OBIO 2017
- Country
- LFVN United States
- OBIO United States
- Employees
- LFVN N/A
- OBIO N/A
- Industry
- LFVN Biotechnology: Pharmaceutical Preparations
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- LFVN Health Care
- OBIO Health Care
- Exchange
- LFVN Nasdaq
- OBIO Nasdaq
- Market Cap
- LFVN 165.9M
- OBIO 151.3M
- IPO Year
- LFVN N/A
- OBIO N/A
- Fundamental
- Price
- LFVN $13.05
- OBIO $2.85
- Analyst Decision
- LFVN Strong Buy
- OBIO Strong Buy
- Analyst Count
- LFVN 2
- OBIO 5
- Target Price
- LFVN $30.50
- OBIO $14.20
- AVG Volume (30 Days)
- LFVN 215.9K
- OBIO 193.1K
- Earning Date
- LFVN 05-06-2025
- OBIO 05-12-2025
- Dividend Yield
- LFVN 1.38%
- OBIO N/A
- EPS Growth
- LFVN 152.87
- OBIO N/A
- EPS
- LFVN 0.70
- OBIO N/A
- Revenue
- LFVN $222,347,000.00
- OBIO $2,886,000.00
- Revenue This Year
- LFVN $17.36
- OBIO $21.38
- Revenue Next Year
- LFVN $9.60
- OBIO $31.89
- P/E Ratio
- LFVN $18.62
- OBIO N/A
- Revenue Growth
- LFVN 8.22
- OBIO 30.23
- 52 Week Low
- LFVN $5.22
- OBIO $2.37
- 52 Week High
- LFVN $27.38
- OBIO $8.87
- Technical
- Relative Strength Index (RSI)
- LFVN 51.11
- OBIO 49.08
- Support Level
- LFVN $12.58
- OBIO $2.61
- Resistance Level
- LFVN $13.53
- OBIO $3.02
- Average True Range (ATR)
- LFVN 0.72
- OBIO 0.18
- MACD
- LFVN 0.13
- OBIO 0.04
- Stochastic Oscillator
- LFVN 74.22
- OBIO 60.19
About LFVN Lifevantage Corporation (Delaware)
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.